Israel state records י"ג בשבט התשס"ח January 20, 2008

צרופים כימיים המשמשים בטיפול בסרטן בלוטת הערמונית	CONJUGATES USEFUL IN THE TREATMENT OF PROSTATE CANCER
[54]
	25.11.1998					[22]
	US	[33]	02.12.1997	[32]	60/067110	[31]
	GB		02.03.1998		9804399.5
Int. Cl.8 A61K 038/04, 038/08, 047/48, A61P 013/08, 035/00, C07K 007/06, 014/47, 017/00						[51]
			MERCK & CO., INC., U.S.A.			[71]
	WO/1999/028345					[87]
ריינהולד כהן ושותפיו, רחוב אחד העם 21 , ת.ד. 4060, תל אביב			REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST., P.O.B. 4060, TEL AVIV 61040			[74]

[57] A conjugate of the formula





wherein:

oligopeptide is an oligopeptide which is specifically recognized by the prostate specific antigen (PSA) and is capable of being proteolytically cleaved by the enzymatic activity of the free prostate specific antigen, X_L is a bond; R is selected from

(a) hydrogen,

(b) –(C=O)R^1a,

(f) ethoxysquarate; and

(g) cotininyl;

R¹ and R² are independently selected from: hydrogen, OH, C₁-C₆ alkyl, C₁-C₆ alkoxy, C₁-C₆ aralkyl and aryl;

R^1a is C₁-C₆-alkyl, hydroxylated C₃-C₈-cycloalkyl, polyhydroxylated C₃-C₈-cycloalkyl, hydroxylated aryl, polyhydroxylated aryl or aryl,

R⁹ is hydrogen, (C₁-C₃ alkyl)-CO, or chlorosubstituted (C₁-C₃ alkyl)-CO;

n is 1, 2, 3 or 4;

p is zero or an integer between 1 and 100;

q is 0 or 1, provided that if p is zero, q is 1;

r is 1, 2 or 3;

t is 3 or 4;

or a pharmaceutically acceptable salt or optical isomer thereof.

__________

136285			[21][11]
תכשירי רוקחות המכילים תרכובת פעילה שאינה יציבה בחומצה			PHARMACEUTICAL COMPOSITIONS CONTAINING AN ACID-LABILE ACTIVE COMPONENT			[54]
	08.12.1998					[22]
	DE	[33]	08.12.1997	[32]	19754324.3	[31]
	DE		20.05.1998		19822549.0
Int. Cl.8 A61K 009/00, 009/50, 047/30, C07D 401/12						[51]
			NYCOMED GMBH, GERMANY			[71]
	WO/1999/029320					[87]
וולף, ברגמן וגולר, רחוב קרן היסוד 19ב' , ת.ד. 1352, ירושלים			WOLFF, BREGMAN AND GOLLER, 19B KEREN HAYESOD ST., P.O.B. 1352, JERUSALEM 91013			[74]

[57] An oral administration form for an acid-labile active compound selected from the group consisting of an acid-labile active proton pump inhibitor, a salt of an acid-labile proton pump inhibitor with a base and a hydrate of a salt of an acid-labile proton pump inhibitor with a base, the form comprising a pharmaceutical auxiliary and a plurality of individual active compound units, wherein the acid-labile active compound in the individual active compound units is surrounded by a mixture of at least one sterol and at least one polymer, by at least one fatty alcohol or by a mixture of at least one fatty alcohol and at least one polymer and/or at least one sterol.

__________

136815			[21][11]
שיטה להגדלת הניצולת של חלבון בקולו – וירוס וחיסון המכיל חלבון זה			METHOD TO INCREASE YIELD OF A PROTEIN IN BACULOVIRUS AND A VACCINE COMPRISING THE SAME			[54]
	17.12.1998					[22]
	EP	[33]	18.12.1997	[32]	97203989.5	[31]
Int. Cl.8 A61K 039/12, C07K 014/185, C12N 015/40, 015/866, C12P 021/00						[51]
			BAYER AKTIENGESELLSCHAFT, GERMANY STICHTING INSTITUUT VOOR DIERHOUDERIJ EN DIERGEZONDHEID, THE NETHERLANDS			[71]
			DIETMAR KRETZDORN, DIRK FRANCISCUS MARINUS VAN DE WIEL, ABRAHAM JOHANNES DE SMIT, ERIK KEES HAMANN, ROBERTUS JACOBUS MARIA MOORMANN			[72]
	WO/1999/031257					[87]
איתן, פרל, לצר וכהן צדק, רחוב שנקר 7 , ת.ד. 12688, הרצליה			EITAN, PEARL, LATZER AND COHEN ZEDEK, P.O.B. 12688, HERZLIYA 46733			[74]

[57] A method to increase yield of a recombinant pestivirus E2 or E^rns protein or immunogenic fragments thereof, or of FSH, produced in insect-cell culture, which comprises: selecting a recombinant baculovirus encoding said protein, and growing insect cells at a cell density of 1 x 10⁵ to 5 x 10⁶ cells/ml, more preferably 5 x 10⁵ to 1.5 x 10⁶ cells/ml in a growth medium in a culture vessel with a sufficient volume to contain at least 2 litres growth medium, and infecting the cells with an inoculum of at least one baculovirus with a multiplicity of infection between 0.005 and 0.00025, calculated from a dilution range of a virus stock.

בקשות חלוקה מבקשה זו שטרם פורסמו.		181468,		The applications for division from this application have not yet been published

__________

138201			[21][11]
שיטוט להכנת שורות תאי עובר או תאים דמויי תאי מקור המיוצרים על ידי השתלת גרעין בין– תאי			METHODS OF PRODUCING EMBRYONIC OR STEM-LIKE CELL LINES PRODUCED BY CROSS-SPECIES NUCLEAR TRANSPLANTATION			[54]
	02.03.1999					[22]
	US	[33]	02.03.1998	[32]	09/032945	[31]
Int. Cl.8 A61K 048/00, C12N 005/00, 015/78						[51]
			UNIVERSITY OF MASSACHUSETTS, U.S.A.			[71]
	WO/1999/045100					[87]
ריינהולד כהן ושותפיו, רחוב אחד העם 21 , ת.ד. 4060, תל אביב			REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST., P.O.B. 4060, TEL AVIV 61040			[74]

[57] A method of producing embryonic or stem-like cells comprising the following steps:

(i) inserting a desired genetically altered differentiated human or mammalian cell or cell nucleus into an enucleated animal oocyte, wherein said oocyte is derived from a different animal species than the human or mammalian cell under conditions suitable for the formation of a nuclear transfer (NT) unit;

(ii) activating the resultant nuclear transfer unit;

(iii) culturing said activated nuclear transfer unit until greater than the 2-cell developmental stage; and

(iv) culturing cell obtained from said cultured NT units to obtain embryonic or stem-like cells.

__________

138306			[21][11]
תכשיר פולינוקלאוטיד, שיטה להכנתו והשימוש בו			POLYNUCLEOTIDE COMPOSITION, METHOD OF PREPARATION AND USE THEREOF			[54]
	12.03.1999					[22]
	US	[33]	13.03.1998	[32]	60/078080	[31]
Int. Cl.8 A61K 009/19, 048/00, C12N 015/10						[51]
			WYETH, U.S.A.			[71]
	WO/1999/004596					[87]
לוצאטו את לוצאטו, גן תעשייה, עומר , ת.ד. 5352, באר שבע			LUZZATTO & LUZZATTO, INDUSTRIAL PARK, OMER, P.O.B. 5352, BEER-SHEVA 84152			[74]

[57] Lyophilized polynucleotide composition comprising:

(a) at least one polynucleotide,

(b) at least one cryoprotectant, wherein the ratio of polynucleotide to cryoprotectant is from about 0.001 to about 1.0 part by weight polynucleotide per 1.0 part by weight cryoprotectant, and

(c) from about 0.5 weight percent to about 6 weight percent water, based on the total weight of the polynucleotide composition;

wherein said polynucleotide composition retains at least 90% supercoil over a time period of at least 10 days at about 37^oC.

__________

138655			[21][11]
שיטות לאבחון סרטן המשתמשות ברעלן כימרי			METHODS OF CANCER DIAGNOSIS USING A CHIMERIC TOXIN			[54]
	24.03.1999					[22]
	US	[33]	24.03.1998	[32]	09/046992	[31]
Int. Cl.8 C07K 007/23, 014/21, 019/00, C12N 015/62, G01N 033/574						[51]
יישום חברה לפיתוח המחקר של האוניברסיטה העברית בירושלים, ירושלים			YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM			[71]
	WO/1999/049059					[87]
ריינהולד כהן ושותפיו, רחוב אחד העם 21 , ת.ד. 4060, תל אביב			REINHOLD COHN AND PARTNERS, 21 AHAD HA'AM ST., P.O.B. 4060, TEL AVIV 61040			[74]

[57] A method for detecting a tumor cell in a biological specimen, comprising contacting the biological specimen with a chimeric toxin which comprises gonadotropin releasing hormone and Pseudomonas exotoxin A and detecting chimeric toxin-bound cells in the specimen.

__________

138812			[21][11]
שימוש ב– גמא –IFN בהכנת תרופות לטיפול בהיפרטרופיה של הלב ובמצבים פתולוגיים קשורים			USE OF IFN-GAMMA IN THE PREPARATION OF MEDICAMENTS FOR TREATING CARDIAC HYPERTROPHY AND ASSOCIATED PATHOLOGICAL CONDITION			[54]
	19.03.1999					[22]
	US	[33]	02.04.1998	[32]	60/080448	[31]
Int. Cl.8 A61K 038/21, A61P 009/00, C07K 014/57						[51]
			GENENTECH, INC., U.S.A.			[71]
	WO/1999/051260					[87]
ש. הורוביץ ושות', בית ציון, שדרות רוטשילד 41-45, תל אביב			S. HOROWITZ & CO., ZION HOUSE, 41-45 ROTHSCHILD BLVD., TEL AVIV 65784			[74]

[57] Use of a therapeutically effective amount of interferon gamma (IFN-γ) in the preparation of a medicament for treating cardiac hypertrophy in a patient diagnosed with pressure overload induced cardiac hypertrophy.

בקשות חלוקה מבקשה זו שטרם פורסמו.

187250,

The applications for division from this application have not yet been published

__________

139668			[21][11]